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Abstract
The etiology and pathogenesis of male breast cancer
(MBC) are poorly known. This is due to the fact that
the disease is rare, and large-scale genetic epidemio-
logic studies have been difficult to carry out. Here, we
studied the frequency of eight recurrent Finnish
BRCA2 founder mutations in a large cohort of 154
MBC patients (65% diagnosed in Finland from 1967
to 1996). Founder mutations were detected in 10
patients (6.5%), eight of whom carried the 9346(2)
A>G mutation. Two novel mutations (4075 delGT and
5808 del5) were discovered in a screening of the
entire BRCA2 coding region in 34 samples. However,
these mutations were not found in the rest of the 120
patients studied. Patients with positive family history
of breast and/or ovarian cancer were often BRCA2
mutation carriers (44%), whereas those with no family
history showed a low frequency of involvement (3.6%;
P < .0001). Finally, we found only one Finnish MBC
patient with 999 del5, the most common founder
mutation in Finnish female breast cancer (FBC)
patients, and one that explains most of the hereditary
FBC and MBC cases in Iceland. The variation in
BRCA2 mutation spectrum between Finnish MBC
patients and FBC patients in Finland and breast
cancer patients in Iceland suggests that modifying
genetic and environmental factors may significantly
influence the penetrance of MBC and FBC in individ-
uals carrying germline BRCA2 mutations in some
populations.
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Introduction
In men, breast cancer is approximately 100 times less
common than in women. Breast cancer accounts for approx-
imately 1%of all cancers inmen. The incidence rates ofmale
breast cancer (MBC) are lower than one case per 100,000
man-years in most populations [1]. In Finland, the age-
adjusted incidence of MBC was 0.4 per 100,000 person-
years in 2001, with about 13 cases diagnosed annually [2].
Genetic risk factors of MBC include Klinefelter’s syndrome
[3,4], as well as mutations of the androgen receptor [5,6],
BRCA1 [7,8], and CHEK2 genes [9]. The strongest known risk
factors for MBC are germline mutations in the BRCA2 gene
[7,10–22]. The reported percentage of BRCA2 mutations in
MBC patients has varied significantly (4–40%) among the
published studies [13,21] (Table 1). Some of this variation
may be due to the small numbers of the study subjects,
different patient ascertainment criteria, as well as the variability
in mutation detection methodology.
In Finland, 15 BRCA1 and 8 BRCA2 mutations have been
reported in FBC patients. Fourteen of these, seven in both
genes, represent recurrent founder mutations that account for
the majority of all detected mutations [23–30]. However, the
frequency of BRCA2 germline mutations in Finnish MBC
patients has remained unknown.
Here, we determined the frequency of eight previously
described Finnish BRCA2 mutations in 154 MBC patients
collected in Finland over a 30-year period using both blood
and paraffin-embedded samples. This represents the largest
study so far reported on MBC and BRCA2 mutations. In
addition, in a subset of 34 patients for whom a blood
specimen was available, we analyzed the entire coding
region of the BRCA2 gene using protein truncation test
(PTT) and denaturing high-performance liquid chromatogra-
phy (DHPLC).
Materials and Methods
Sample Collection
We reviewed all men with an ICD code for breast cancer
notified to the nationwide, population-based Finnish Cancer
Abbreviations: DHPLC, denaturing high-performance liquid chromatography; FBC, female
breast cancer; MBC, male breast cancer; PTT, protein truncation test
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Registry between 1967 and 1996, and those 237 with
microscopically confirmed diagnosis of carcinoma were eli-
gible for the study. We linked the personal identification
codes of these MBC patients with data from the Finnish
Population Register Centre, providing us with additional
information on vital status, possible date of death, or emi-
gration. All first-degree relatives of the MBC patients, and
second-degree relatives when possible, were then identified
from the population and parish registries. Cancer diagnoses
of the relatives were also identified by linking the personal
identification codes of the relatives back to the Cancer
Registry. The study protocol was approved by the Ethical
Committee of the Tampere University Hospital and the
Ministry of Social Affairs and Health in Finland.
Of 237 patients, 79 (33%) were alive, and they were
approached through the attending physicians. We obtained
a written informed consent to participate in the study and a
blood sample from 37 patients. A questionnaire on malig-
nancies in the family was also received. Paraffin-embedded
tissue samples were obtained from 130 patients; most of
these patients had died of the disease. In 122 of the paraffin-
embedded tumors, breast cancer diagnosis was confirmed
by a pathologist (T.K.), leading to abandonment of eight
samples.
Mutation Detection
DNA was extracted from blood samples using Puregene
(Gentra Systems, Minneapolis, MN) or from paraffin-embed-
ded nonmalignant tissues using QIAamp DNA Mini Kit
(Qiagen, Valencia, CA). Sufficient amount of DNA was ob-
tained from 156 samples. Eight BRCA2 mutations, previ-
ously found to be present in the Finnish FBC patients, were
analyzed in all 156 samples. The mutations screened
were 999 del5, 4081 insA, 5797 G>T, 6495/6496 G>C,
delCA, 6503 delTT, 7708 C>T, 8555 T>G, and 9346(2)
A>G (NCBI RefSeq mRNA accession no. NM 000059).
Short (80–150 bp) fragments around the possible mutation
sites were amplified by polymerase chain reaction (PCR)
using genomic DNA. For each primer set, one primer was
5V-biotinylated.
Mutation detection was done using solid-phase minise-
quencing (single-base extension reaction) as previously
described [31] using streptavidin-coated microtiter plates
manufactured from scintillating plastic (Wallac; Perkin Elmer,
Turku, Finland) and 1450 MicroBeta PLUS Liquid scintilla-
tion counter by the same manufacturer. PCR primers and
minisequencing detection primers are available upon re-
quest. Mutation-positive and mutation-negative controls as
well as a negative control for the PCR reaction were in-
cluded in each analysis. The results were confirmed by
direct sequencing using ABI PRISM 310 Genetic Analyzer
and Dye Terminator Cycle Sequencing Ready Reaction Kit
(Perkin Elmer) according to the manufacturer’s instructions.
Two DNA samples from paraffin-embedded tissues were
excluded because of conflicting mutation results.
BRCA2 founder mutation was found in 3 of 37 patients
from whom DNA samples from whole blood were available,
and thus 34 samples were screened for the presence of
additional BRCA2 mutations. The entire coding region of
BRCA2 was analyzed using PTT for exons 10 and 11, and
DHPLC for exons 2 to 9 and 12 to 27, including also the first
300 bp of exons 10 and 11. Samples with truncated PTT
bands or aberrant DHPLC chromatograms were sequenced,
using a new PCR product as a template [32,33].
Statistical Analyses
Statistical analyses were performed using GraphPad
InStat version 2.04a (GraphPad Software, San Diego,
CA). Continuous parametric variables were shown as
mean and standard deviation, and comparisons were made
with Student’s t test. Associations between categorical
Table 1. Frequency of BRCA2 Mutations in MBC Patients According to Family History of Breast –Ovarian Cancer.
Study Population Number of Patients Screening Strategy Percentage of BRCA2 Mutation Carriers* Reference
All Patients Patients with Positive Family History
Canada 14 Entire gene 14 (2/14) 29 (2/7) [10]
France 12y Entire gene 25 (3/12) 25 (3/12) [11]
Hungary 18 Entire gene 33 (6/18) 0 (0/4) [12]
Iceland 30 Founder 40 (12/30) 90 (9/10) [13]
Israel 124 Founder 12 (15/124) – [7]
Italy 25 Entire gene 12 (3/25) 29 (2/7) [14]
Poland 37 Entire gene 11 (4/37) 20 (1/5) [15]
Spain 17z Entire gene 18 (3/17) 33 (3/9) [16]
Sweden 34 Entire gene 21 (7/34) 20 (1/5) [17]
UK 28 Entire gene 7 (2/28) 10 (1/10) [18]
UK 33§ Entire gene 36 (12/33) 40 (12/30) [19]
UK 94 Entire gene 5 (5/94) 16 (3/19) [20]
USA 54 Entire gene 4 (2/54) 6 (1/16) [21]
USA 50 Entire gene 14 (7/50) 15 (6/40) [22]
Total 570 7 (83/570)
Finland 154 Founder/entire gene 8 (12/154) 44 (7/16) Present study
*Missense mutations with unknown significance excluded.
yOnly cases with positive family history were included.
zSix females with breast cancer and a first-degree relative with MBC included.
§Seventeen females with breast cancer and a first-degree or second-degree relative with MBC included.
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variables were analyzed by Fisher’s exact test and chi-
square analysis.
Results
Mutations
We screened eight previously described Finnish BRCA2
founder mutations in 154 MBC patients, and three different
mutations [999 del5, 7708 C>T, and 9346(2) A>G] were
found. Altogether, 10 (6.5%) patients were mutation-positive
(Table 2). Eight (5.2%) patients carried the 9346(2) A>G
mutation.
PTT and DHPLC screening of 34 patients revealed two
novel mutations (5.9%): 4075 delGT and 5808 del5. Addi-
tionally, 12 different silent polymorphisms were detected
(data not shown). Subsequently, the 4075 delGT and 5808
del5 mutations were studied in all 154 samples, but no
additional mutation carriers were found. Taken together,
BRCA2 mutations were present in 12 (7.8%) MBC patients.
Characteristics of Mutation Carriers
MBC patients with BRCA2 mutations were only slightly
younger (mean 64.9 years; SD 11.9; range 46–91) than
noncarriers (mean 65.7 years; SD 12.4; range 30–94) at the
time of diagnosis; this difference did not reach statistical
significance. None of the four patients under 40 years, and
only two of the 17 patients under 50 years of age at the time
of diagnosis, carried a mutation.
Sixteen MBC patients had at least one first-degree or
second-degree female relative with breast cancer. Seven of
these MBC patients (44%) carried a BRCA2 mutation,
whereas only 5 of 138 (3.6%) patients without family history
of breast cancer had a BRCA2 mutation. This difference
was statistically highly significant [P < .0001; OR = 20 (95%
CI 5–76)].
Three MBC patients had a first-degree or second-degree
relative with ovarian cancer, and two of these MBC patients
carried BRCA2 mutations: 4075 delGT and 9346(2) A>G
(Table 2). Two mutation-positive MBC patients were found to
have relatives with MBC. Additionally, two initially unrelated
MBC patients with no BRCA2 mutations were found to be
related with each other (second-degree relatives) in more
detailed pedigree analysis. Unfortunately, only tissue sam-
ples were available from these patients, and we were not
able to screen the entire BRCA2 gene for mutations.
Discussion
We report here the frequency of eight different, previously
found Finnish BRCA2 mutations in 154 Finnish MBC pa-
tients, as well as the screening of the entire coding sequence
of the BRCA2 gene in 34 MBC patients for whom blood
samples were available. To our knowledge, this is the largest
set of MBC patients included in a systematic screening of
BRCA2 mutations. The patients comprised 65% of all MBC
patients identified in Finland over a 30-year period, providing
a higher coverage of cases in the source population than in
many previous studies.
The overall BRCA2 mutation frequency was 7.8% in the
present study, which is slightly lower than BRCA2 mutation
frequencies in MBC in most previously published studies
[7,10–22] (Table 1). However, if we expect the rate of spo-
radic mutations among the 154 to be the same as among the
Table 2. Characteristics of MBC Patients with BRCA2 Mutations.
Patient Mutation Effect Age at
Diagnosis
(years)
Histologic
Type
(Grade)
Family History of Cancer Among First-Degree and Second-Degree Relatives
Type of Relative (Age at Diagnosis)
Breast Cancer Other Cancers
Y170 999 del5 Frameshift 46 IDC (3) S (25), S (45), S (54), S (65, 67)* M stomach (76), F prostate (63),
B lung (64), PA uterine (61),
PA fallopian tube (79)
Y047 4075 delGT Frameshift 58 ILC B (78) S ovary (67), S cervical (71)
Y099 5808 del5 Frameshift 66 IDC (3) MA (76), PA (83) MA skin (97), GD leukemia (5), B skin (74),
BD chorion (30)
Y021 7708 C>T Nonsense 71 IDC (3) M (80), S (50) F skin (NA), S liver (78), SD brain (8)
Y063-17 9346(2) A>G Splice site 67 IDC (2) SS (71), SD (36), SD (49),
SD (50) a, SD (54) b
SD ovarian (58), D uterine (55), So prostate (60),
B colon (87), S laryngeal (NA), SD cervical (39),
SD cervical (47) a, SD lymphoma (69) b
Y076 9346(2) A>G Splice site 64 IDC (3)
Y084 9346(2) A>G Splice site 49 IDC (2) S (73) F prostate (69), F skin (47), B prostate (58)
Y089 9346(2) A>G Splice site 66 IDC (2)
Y095 9346(2) A>G Splice site 69 IDC (3) D (44) c, S (80) D chorion (33) c, B prostate (69)
Y103 9346(2) A>G Splice site 91 IDC (1)
Y115 9346(2) A>G Splice site 57 ILC
Y157 9346(2) A>G Splice site 75 IDC (2) B stomach (84), So prostate (56)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
M, mother; F, father; S, sister; B, brother; D, daughter; So, son; GD, granddaughter; PA, paternal aunt; PU, paternal uncle; MA, maternal aunt; SD, sister’s
daughter; SS, sister’s son; BD, brother’s daughter; NA, not available.
a, b, c, same individuals.
*Bilateral breast cancer.
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34 patients screened comprehensively for BRCA2 mu-
tations, we could estimate that the total mutation burden,
including both recurrent and sporadic mutations, is approx-
imately 12% to 13% (6.5% + 5.9%). This is well in line with
those found in previous studies, where the entire coding
sequence of all patients was analyzed [7,10–22] (Table 1).
In our study, 10.4% (16/154) of the MBC cases had a
positive family history of breast cancer, and as many as sev-
en of these 16 patients (44%) carried a BRCA2 mutation.
The percentage of family history–positive MBC patients with
BRCA2 mutations has been found to range from 0% to 90%
[7,10–22] (Table 1). In Iceland and Finland where strong
founder effects can be found, a larger proportion of family
history–positive patients carried a BRCA2 mutation com-
pared to other populations [13]. In contrast, BRCA2 muta-
tions were rare (3.6%) among Finnish MBC patients with
negative family history of breast and/or ovarian cancer. Many
of the other MBC studies have reported similar results, with a
range of BRCA2 positivity in family history–negative cases
from 0% to 15% [7,10–22] (Table 1). On the other hand, up
to 21% of family-negative MBCs carried a BRCA2 mutation
in Sweden (6/29) and 43% (6/14) in Hungary [17,12].
The frequencies of different BRCA2 mutations varied
greatly among Finnish MBC and female breast cancer
(FBC) populations (Figure 1). Among 1035 unselected
Finnish FBC patients, 1.8% carried one of the BRCA1
(0.4%) or BRCA2 (1.4%) founder mutations [27]. In MBC pa-
tients, the most common BRCA2 mutation was 9346(2)
A>G, with a frequency of 67% (8/12 BRCA2 mutation-
positive cases). In unselected FBC population, the
9346(2) A>G mutation was the second most common
mutation with a much lower frequency (27%; 4/15) [28].
The difference in 9346(2) A>G mutation frequencies was
significant between males and females (P = .038; OR = 5.5;
95% CI 1–29). In contrast, only one MBC patient carried the
999 del5 mutation, which is the most common BRCA1/2
founder mutation in Finland [29]. Up to 40% of all Icelandic
MBC patients carries this mutation [13]. All 10 MBC founder
mutation carriers originated from the same regions in Finland
as the FBC patients carrying the corresponding founder
mutations [28]. The low number of 999 del5mutations cannot
be explained by simple selection bias because dozens of
samples were available from the two founder areas of this
mutation [13]. Our findings and those by Thorlacius et al. [13]
therefore point to additional genetic modifier loci, or possibly
environmental factors that differentially influence MBC and
FBC penetrance among different BRCA2 mutation carriers.
In summary, we report here a large genetic epidemiologic
study that suggested an approximately 13% frequency of
BRCA2 mutations in unselected Finnish MBC patients.
Founder mutations account for the majority of these, with
one particular mutation [9346(2) A>G] showing a very
high frequency among MBC patients. In contrast, the most
common Finnish founder mutation in FBC patients (999 del5)
was seen only in one MBC patient. Interestingly, the same
999 del5 founder mutation accounts for the majority of both
male and female hereditary breast cancers in Iceland [13].
Although the numbers of BRCA2-positive MBC cases are
still relatively small, our results point to some frequency
differences of individual BRCA2 founder mutations when
compared to analogous nationwide study of FBC. This may
reflect differences in modifier loci, or, equally likely, environ-
mental differences (such as hormonal and dietary) that
influence the penetrance of different BRCA2 mutations be-
tween female and male populations as well as between
different populations.
Acknowledgements
We thank the patients and doctors who participated in the
study, Kati Rouhento for technical assistance, and Kristiina
Selkee for her help in patient contacts.
References
[1] Sasco AJ, Lowenfels AB, and Pasker-de Jong P (1993). Review article:
epidemiology of male breast cancer. A meta-analysis of published
case–control studies and discussion of selected aetiological factors.
Int J Cancer 53, 538–549.
[2] The Finnish Cancer Registry (2002). Cancer Statistics (Last updated on
November 21, 2002 (http://www.cancerregistry.fi)).
[3] Evans DB and Crichlow RW (1987). Carcinoma of the male breast and
Klinefelter’s syndrome: is there an association? CA Cancer J Clin 37,
246–251.
[4] Hultborn R, Hanson C, Kopf I, Verbiene I, Warnhammar E, and
Weimarck A (1997). Prevalence of Klinefelter’s syndrome in male
breast cancer patients. Anticancer Res 17, 4293–4297.
Figure 1. BRCA2 mutation spectrum among mutation-positive Finnish FBC [27] and MBC populations.
544 BRCA2 in Male Breast Cancer Syrja¨koski et al.
Neoplasia . Vol. 6, No. 5, 2004
[5] Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D,
Barrett-Lee P, Easton DF, Ponder BA, and Stratton MR (1992).
A germline mutation in the androgen receptor gene in two broth-
ers with breast cancer and Reifenstein syndrome. Nat Genet 2,
132–134.
[6] Lobaccaro JM, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J,
Lesimple T, Heron JF, Pujol H, and Sultan C (1993). Male breast can-
cer and the androgen receptor gene. Nat Genet 5, 109–110.
[7] Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P,
Resnick MB, Lifzchiz-Mercerl B, Lew S, and Iscovich J (1999). Founder
BRCA1/2 mutations among male patients with breast cancer in Israel.
Am J Hum Genet 65, 1800–1802.
[8] Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter
B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, and Critchfield GC
(2002). Clinical characteristics of individuals with germline mutations
in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol
20, 1480–1490.
[9] Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M,
de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E,
van Veghel-Plandsoen M, Elstrodt F, vanDuijn C, Bartels C, Meijers
C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal
S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans
DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang
HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL,
Weber B, Rahman N, Stratton MR, and CHEK2-Breast Cancer Consor-
tium MR (2002). Low-penetrance susceptibility to breast cancer due
to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Nat Genet 31, 55–59.
[10] Wolpert N, Warner E, Seminsky MF, Futreal A, and Narod SA (2000).
Prevalence of BRCA1 and BRCA2 mutations in male breast cancer
patients in Canada. Clin Breast Cancer 1, 57–63.
[11] Pages S, Caux V, Stoppa-Lyonnet D, and Tosi M (2001). Screening
of male breast cancer and of breast – ovarian cancer families for
BRCA2 mutations using large bifluorescent amplicons. Br J Cancer
84, 482–488.
[12] Csokay B, Udvarhelyi N, Sulyok Z, Besznyak I, Ramus S, Ponder B,
and Olah E (1999). High frequency of germ-line BRCA2 mutations
among Hungarian male breast cancer patients without family history.
Cancer Res 59, 995–998.
[13] Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson
JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, and Eyfjord JE
(1996). A single BRCA2 mutation in male and female breast cancer
families from Iceland with varied cancer phenotypes. Nat Genet 13,
117–119.
[14] Ottini L, Masala G, D’Amico C, Mancini B, Saieva C, Aceto G, Gestri D,
Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S,
Mariani-Costantini R, and Palli D (2003). BRCA1 and BRCA2 mutation
status and tumor characteristics in male breast cancer: a population-
based study in Italy. Cancer Res 63, 342–347.
[15] Kwiatkowska E, Teresiak M, Lamperska KM, Karczewska A,
Breborowicz D, Stawicka M, Godlewski D, Krzyzosiak WJ, and
Mackiewicz A (2001). BRCA2 germline mutations in male breast can-
cer patients in the Polish population. Hum Mutat 17, 73.
[16] Diez O, Cortes J, Domenech M, Pericay C, Brunet J, Alonso C, and
Baiget M (2000). BRCA2 germ-line mutations in Spanish male breast
cancer patients. Ann Oncol 11, 81–84.
[17] Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, and
Borg A˚ (1998). BRCA2 germ-line mutations are frequent in male breast
cancer patients without a family history of the disease. Cancer Res 58,
1367–1371.
[18] Mavraki E, Gray IC, Bishop DT, and Spurr NK (1997). Germline BRCA2
mutations in men with breast cancer. Br J Cancer 76, 1428–1431.
[19] Evans DG, Bulman M, Young K, Gokhale D, and Lalloo F (2001). High
detection rate for BRCA2 mutations in male breast cancer families from
North West England. Fam Cancer 1, 131–133.
[20] Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton
DF, and Pharoah PD (2002). BRCA1 and BRCA2 mutations in a popu-
lation-based study of male breast cancer. Breast Cancer Res 4, R2.
[21] Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G,
Ponder BA, and Anton-Culver H (1997). Mutation analysis of BRCA1
and BRCA2 in a male breast cancer population. Am J Hum Genet 60,
313–319.
[22] Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau
L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D,
Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard
J, Garber J, Merajver S, and Weber BL (1996). BRCA2 germline muta-
tions in male breast cancer cases and breast cancer families. Nat
Genet 13, 123–125.
[23] Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus
L, Kainu T, Syrja¨koski K, Pyrho¨nen S, Kallioniemi OP, Muhonen I, Luce
M, Frank TS, and Nevanlinna H (1997). Low proportion of BRCA1 and
BRCA2 mutations in Finnish breast cancer families: evidence for addi-
tional susceptibility genes. Hum Mol Genet 6, 2309–2315.
[24] Vehmanen P, Friedman LS, Eerola H, Sarantaus L, Pyrhonen S,
Ponder BA, Muhonen T, and Nevanlinna H (1997). A low proportion
of BRCA2 mutations in Finnish breast cancer families. Am J Hum
Genet 60, 1050–1058.
[25] Huusko P, Pa¨a¨kko¨nen K, Launonen V, Po¨yho¨nen M, Blanco G, Kauppila
A, Puistola U, Kiviniemi H, Kujala M, Leisti J, and Winqvist R (1998).
Evidence of founder mutations in Finnish BRCA1 and BRCA2 families.
Am J Hum Genet 62, 1544–1548.
[26] Sarantaus L, Auranen A, and Nevanlinna H (2001). BRCA1 and
BRCA2 mutations among Finnish ovarian carcinoma families. Int J
Oncol 18, 831–835.
[27] Syrja¨koski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K,
Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, and
Nevanlinna H (2000). Population-based study of BRCA1 and BRCA2
mutations in 1035 unselected Finnish breast cancer patients. J Natl
Cancer Inst 92, 1529–1531.
[28] Sarantaus L,HuuskoP,EerolaH,LaunonenV,VehmanenP,RapakkoK,
Gillanders E, Syrja¨koski K, KainuT, Vahteristo P, KraheR, Pa¨a¨kko¨nenK,
Hartikainen J, Blomqvist C, Lo¨ppo¨nen T, Holli K, Ryyna¨nenM, Bu¨tzowR,
BorgA˚,WastesonArverB,HolmbergE,MannermaaA,KereJ,Kallioniemi
OP, Winqvist R, and Nevanlinna H (2000). Multiple founder effects
and geographical clustering of BRCA1 and BRCA2 families in Finland.
Eur J HumGenet 8, 757–763.
[29] Barkardottir RB, Sarantaus L, Arason A, Vehmanen P, Bendahl PO,
Kainu T, Syrja¨koski K, Krahe R, Huusko P, Pyrho¨nen S, Holli K,
Kallioniemi OP, Egilsson V, Kere J, and Nevanlinna H (2001). Hap-
lotype analysis in Icelandic and Finnish BRCA2. Eur J Hum Genet
9, 773–779.
[30] Vahteristo P, Eerola H, Tamminen A, Blomqvist C, and Nevanlinna H
(2001). A probability model for predicting BRCA1 and BRCA2 muta-
tions in breast and breast –ovarian cancer families. Br J Cancer 84,
704–708.
[31] Syva¨nen AC (1998). Solid-phase minisequencing as a tool to detect
DNA polymorphism. Methods Mol Biol 98, 291–298.
[32] Ha˚kansson S, Johannsson O, Johansson U, Sellberg G, Loman N,
Gerdes AM, Holmberg E, Dahl N, Pandis N, Kristoffersson U, Olsson
H, and Borg A˚ (1997). Moderate frequency of BRCA1 and BRCA2
germ-line mutations in Scandinavian familial breast cancer. Am J
Hum Genet 60, 1068–1078.
[33] Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muhr D, Pages S,
Sandberg T, Caux V, Moeslinger R, Langbauer G, Borg A, and Oefner
P (1999). Denaturing high-performance liquid chromatography detects
reliably BRCA1 and BRCA2 mutations. Genomics 62, 369–376.
BRCA2 in Male Breast Cancer Syrja¨koski et al. 545
Neoplasia . Vol. 6, No. 5, 2004
